Last reviewed · How we verify

early enteral nutrition

Nanjing University School of Medicine · FDA-approved active Small molecule Quality 55/100

Early enteral nutrition (EEN) is a marketed nutritional intervention developed by Nanjing University School of Medicine, supported by extensive clinical evidence from 100 trials and 1,113 publications. The approach involves providing nutrition directly into the gastrointestinal tract during acute illness, demonstrating clinical benefits across acute pancreatitis, critical illness, and postoperative recovery. EEN represents a paradigm shift from traditional parenteral nutrition, offering improved outcomes, reduced infection rates, and better preservation of gut barrier function. With robust clinical validation and widespread adoption in clinical practice, EEN has become standard-of-care in multiple acute care settings. The extensive publication record underscores its clinical significance and establishes it as a foundational therapeutic strategy in critical care and surgical recovery protocols.

At a glance

Generic nameearly enteral nutrition
SponsorNanjing University School of Medicine
Drug classNutritional intervention / Dietary management strategy
TargetGastrointestinal tract mucosa and intestinal barrier function
ModalitySmall molecule
Therapeutic areaMetabolic
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: